Intraocular Pressure Change Following Intravitreal Injection of Anti-vascular Endothelial Growth Factor Agent
- Sponsor
- Prince of Songkla University
- Study ID
- NCT02474225
- Status
- Completed
Conditions
- Intraocular Pressure
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 85 Years
- Healthy Volunteers
- Not accepted
Interventions
- Intravitreal injection (bevacizumab or ranibizumab) — DRUGThe intravitreal anti-vascular endothelial growth factor agent of 0.1 ml of bevacizumab (2.5 mg/0.1 ml) or ranibizumab (1 mg/0.1 ml)
Study Details
The introduction of additional fluid into the vitreous cavity by intravitreal therapy would be expected to cause an immediate rise in the intraocular pressure. This transient, short-term intraocular pressure elevation (lasting up to 30 minutes) after intravitreal anti-vascular endothelial growth factor therapy has been well describe. The investigators aim to study the prevalence of the sustained intraocular pressure elevation associated with intravitreal injection of anti-vascular endothelial growth factor agents.
Key Dates
- First listed
- Jun 17, 2015
- Start date
- Dec 31, 2013
- Status verified
- Jun 2015
- Primary completion
- May 31, 2015
- Completion
- May 31, 2015
Study Design
- Enrollment
- 70 participants (actual)
Primary Outcome Measure
Change from baseline in intraocular pressure [ Time Frame: 6-month after injection ]
Related Studies
- External Influences Upon Ocular HomeostasisEnrolling By Invitation · Vanderbilt University Medical Center · Nashville, Tennessee
- IOP Elevation StudyRecruiting · NYU Langone Health · New York, New York
- Effect of Position and Anesthetic Choice in Intraocular Pressure in Robotic GYN (Gynecologic) Oncology PatientsPHASE4 · Recruiting · University of Florida · Gainesville, Florida
- Effect of Raised End-Tidal pCo2 on Choroidal VolumeRecruiting · University of Pittsburgh · Pittsburgh, Pennsylvania